Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | PYGM | P11217 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
| ▸ | TK2 | O00142 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxribtimine SCHEMBL787714 | 0.88 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| Doxribtimine SCHEMBL6518312 | 0.88 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| Cytidine SCHEMBL27688434 | 0.88 | LMNA (0.77) | LMNATHRBMTORMDM2NCOA1 | |
| Doxecitine SCHEMBL9803658 | 0.87 | LMNA (0.50) | LMNATK2 | |
| Doxribtimine SCHEMBL29124320 | 0.85 | P2RY2 (0.60) | LMNATHRBMTORMDM2NCOA1 | |
| Lamivudine SCHEMBL22364335 | 0.82 | ALB (0.65) | LMNATK2 | |
| Stavudine SCHEMBL8185422 | 0.81 | LMNA (0.60) | LMNATK2 | |
| Stavudine SCHEMBL7053412 | 0.81 | LMNA (0.60) | LMNATK2 | |
| Uridine SCHEMBL27538938 | 0.80 | SLC28A1 (0.56) | LMNASLC28A1SLC28A2SLC29A1SLC28A3 | |
| Doxribtimine SCHEMBL3951759 | 0.80 | TK1 (0.56) | LMNATK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056441-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS INC (US) | 2022-02-24 | — | — | US | disclosed |
| US-10889815-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10662428-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190233821-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2019-08-01 | — | — | US | disclosed |
| US-10351852-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190194658-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190010497-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS INC (US) | 2019-01-10 | — | — | US | disclosed |
| US-20180245083-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS INC (US) | 2018-08-30 | — | — | US | disclosed |
| US-10000754-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9957517-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-1572067-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005041859-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY. | SIRNA THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005019453-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050032733-A1 | siNA molecule comprising a double-stranded structure that down-regulates expression of Hepatitis B Virus (HBV) , wherein said siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference | SIRNA THERAPEUTICS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050020525-A1 | first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence chemically modified so that it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; pharmaceutical use such as viricide | SIRNA THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | US | disclosed |
| US-20040192626-A1 | siNA molecule comprising a double-stranded structure that down-regulates expression of a target nucleic acid, wherein said siNA molecule does not require a 2'-hydroxyl group containing ribonucleotide; treating viral diseases such as SARS (severe acute respiratory syndrome virus), herpes, hepatitis, HIV | BANK OF AMERICA, N.A. | 2004-09-30 | — | — | US | disclosed |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | RIBOZYME PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
| US-20030130186-A1 | Conjugates and compositions for cellular delivery | RIBOZYME PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2002094185-A2 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192626-A1 | siNA molecule comprising a double-stranded structure that down-regulates expression of a target nucleic acid, wherein said siNA molecule does not require a 2'-hydroxyl group containing ribonucleotide; treating viral diseases such as SARS (severe acute respiratory syndrome virus), herpes, hepatitis, HIV | SARS1, EIF2AK2, MAVS | LMNA 3025/4885THRB 1429/4885MTOR 932/4885 |
| US-10662428-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | LMNA 3645/4885THRB 1631/4885MTOR 1835/4885 |
| US-20050020525-A1 | first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence chemically modified so that it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; pharmaceutical use such as viricide | AGO2, SRRT, ADAR | LMNA 3478/4885THRB 1891/4885MTOR 3407/4885 |
| US-20030130186-A1 | Conjugates and compositions for cellular delivery | ALB, FUT5, RNGTT | LMNA 1219/4885THRB 426/4885MTOR 4775/4885 |
| US-20190010497-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | LMNA 3645/4885THRB 1631/4885MTOR 1835/4885 |
| US-20190194658-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | LMNA 3645/4885THRB 1631/4885MTOR 1835/4885 |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | LMNA 1747/4885THRB 205/4885MTOR 4762/4885 |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | LMNA 1747/4885THRB 205/4885MTOR 4762/4885 |
| US-10889815-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | LMNA 3645/4885THRB 1631/4885MTOR 1835/4885 |
| US-20050032733-A1 | siNA molecule comprising a double-stranded structure that down-regulates expression of Hepatitis B Virus (HBV) , wherein said siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference | SNRPE, SIN3A, SRRT | LMNA 1926/4885THRB 609/4885MTOR 1195/4885 |
| US-20220056441-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | AGO2, SNRPE, SRRT | LMNA 3645/4885THRB 1631/4885MTOR 1835/4885 |
| US-20190233821-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | LMNA 3645/4885THRB 1631/4885MTOR 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.